Clinical Trials Browser

Recurrence × BIIB022 × Clear all

NCT00555724 2017-01-09

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Phase 1 Completed

Recurrence